GN RESOUND
Report
- Report Number
- 3005650109-2024-00072
- Event Type
- Malfunction
- Date Received
- September 20, 2024
- Date of Event
- August 20, 2024
- Report Date
- December 12, 2024
- Manufacturer
- GN HEARING A/S
- Product Code
- OSM
- UDI-DI
- 05708296178865
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NL
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
- Health Professional
- Yes
Narratives
MANUFACTURER'S REF# (B)(4). THIS IS AN INITIAL REPORT. INVESTIGATION IS STILL IN PROGRESS; A FINAL REPORT WILL BE SUBMITTED UPON COMPLETION. 17-OCT-2024: DEVICE HAS BEEN SENT TO VARTA FOR DEVICE INVESTIGATION. A FINAL REPORT WILL BE SUBMITTED UPON COMPLETION.
MANUFACTURER'S REF (B)(4). THIS IS AN INITIAL REPORT. INVESTIGATION IS STILL IN PROGRESS; A FINAL REPORT WILL BE SUBMITTED UPON COMPLETION.
MANUFACTURER'S REF# SF 03887343. THIS IS AN INITIAL REPORT. INVESTIGATION IS STILL IN PROGRESS; A FINAL REPORT WILL BE SUBMITTED UPON COMPLETION. 17-OCT-2024: DEVICE HAS BEEN SENT TO VARTA FOR DEVICE INVESTIGATION. A FINAL REPORT WILL BE SUBMITTED UPON COMPLETION. 12-DEC-2024: DEVICE INVESTIGATION: ON 15-NOV-2024 DEVICE INVESTIGATION FROM VARTA RECEIVED. THE DEVICE INVESTIGATION CONCLUDED: VARTA STARTED AN EXTENSIVE PROGRAM TO EVALUATE THE ROOT CAUSE FOR CELL EXPANSION. AS OF TODAY, THERE IS NO CLEARLY DEFINED ROOT CAUSE. IT SEEMS THAT THE BATTERY ITSELF IS NOT ONLY INFLUENCING CELL EXPANSION. THERE ARE MAYBE INFLUENCES FROM HEARING AID END USER. IN ALL CASES, WHICH WERE INVESTIGATED AT VARTA, THE EXPANSION HAPPENED DUE TO AN ABNORMAL USE, E.G. CELL IS BEING CHARGED, REPEATED USE OF EMPTY, COMPLETELY DISCHARGED CELL. CELL HAS NOT BEEN REMOVED FROM UNUSED HEARING AID FOR LONGER PERIOD WHEN STORED IN A BOWL IN BULK, MUTUAL SHORT CIRCUIT OCCUR CONSIDERING THE FACTORS AT HAND, IT WAS NOT POSSIBLE TO DETERMINE THE REAL CAUSE OF THE EXPANSION BASED ON THE INVESTIGATION RESULTS AND THE AVAILABLE INFORMATION. CLINICAL ASSESSMENT CONCLUDED: CLINICAL CONCLUSION IS THAT THE EXPANDED BATTERY HAS NOT CAUSED PHYSICAL HARM TO THE PATIENT AND NO MEDICAL TREATMENT WAS PRESCRIBED. CLINICAL EVALUATION ACCORDING CLIN EVAL PLAN&RPT,HA&TSG: LEAKAGE FROM BATTERIES CAN RESULT FROM BATTERY EXPLOSION OR THE BATTERY CAN HAVE A HOLE THAT ALLOWS MATERIAL TO LEAK OUT. ZINC-AIR AND SILVER ZINC BATTERIES USED WITH HEARING AIDS ARE KNOWN TO HAVE A LOW RISK OF LEAKING AND "EXPLODING". ZINC-AIR BATTERIES ARE USED IN THE NON-RECHARGEABLE HEARING AIDS AND SILVER ZINC BATTERIES ARE USED IN THE Z-POWER SOLUTION. THE RISK INCREASES IF THE BATTERY IS EXPOSED TO EXCESSIVE HEAT. EVEN WITHOUT EXCESSIVE HEAT, IN RARE CASES, GAS CAN BE GENERATED INSIDE THE BATTERY AND IF THE PRESSURE BUILDS UP TO MORE THAN THE CELL CAN WITHSTAND, A RUPTURE CAN OCCUR. ALL MATERIALS SHOULD BE PUT IN A CONTAINER AND CARE SHOULD BE TAKEN TO AVOID SKIN BEING EXPOSED TO RUPTURED BATTERY. IF SKIN IS EXPOSED, IT SHOULD BE FLUSHED WITH LUKEWARM WATER FOR AT LEAST 15 MINUTES. IMMEDIATE MEDICAL ATTENTION SHOULD BE SOUGHT IF EYES ARE EXPOSED. BATTERY LEAKAGE CAN IN SOME CASES BE PREVENTED IF THE HEARING AIDS ARE DRIED OUT AFTER USE BY OPENING THE BATTERY DOOR. FURTHER, BATTERIES THAT ARE EXPIRED ARE MORE LIKELY TO LEAK. THE USER GUIDE INCLUDES RECOMMENDATIONS ON BOTH HEARING AID DRYING AND ONLY TO USE BATTERIES WITH A REMAINING SHELF LIFE OF ONE YEAR OR MORE. THE USER GUIDE CONTAINS INFORMATION ONLY TO USE QUALITY BATTERIES AS WELL AS RINSING WITH LUKEWARM WATER IF EXPOSED TO BATTERY LEAKAGE. THERE ARE NO NEW CLINICAL ASPECTS (E.G., UNFORESEEN USE OR CLINICAL CONDITIONS) DISCOVERED FROM THIS EVENT. THEREFORE, IT IS CONCLUDED THAT THE CURRENT CLINICAL EVALUATION AND RISK/BENEFIT CONCLUSION HEREIN ARE SUFFICIENT. RISK ASSESSMENT CONCLUDED: RISKS RELATED TO ELECTRICAL ENERGY, ARE GENERALLY KNOWN, CONSIDERED IN RISK ANALYSIS, MITIGATED AND COMMUNICATED TO THE USER. THIS RISK IS DEEMED TO BE ACCEPTABLE. MANUFACTURER'S INVESTIGATION IS FINAL. THIS IS A FINAL REPORT.
IT WAS REPORTED THAT A HEARING AID OVERHEATED AND EXPLODED (LOUD BANG) WHILE WEARING DEVICE IN EAR. USER REMOVED THE DEVICE AND SAW THE HOUSING WAS DISLOCATED AND THE DEVICE FELT VERY WARM. NO PHYSICAL HARM WAS REPORTED, NO INCREASE OF HEARING LOSS OR TINNITUS AS A RESULT OF THIS WAS REPORTED. THE USER HAS NOT SEEN A DOCTOR. HOT FEELING AND SCARRING (NO PHYSICAL HARM) WAS REPORTED. USER WAS WEARING THE HEARING AID DURING TRIAL PERIOD. WAS USING BATTERIES FROM VARTA CALLED POWER ONE EVOLUTION, WHICH WAS PROVIDED BY THE HEARING CARE PROVIDER. FURTHER INVESTIGATION TO BE CONDUCTED. 17-OCT-2024: DESPITE ATTEMPTS NO FURTHER FOLLOW UP INFORMATION RECEIVED.
IT WAS REPORTED THAT A HEARING AID OVERHEATED AND EXPLODED (LOUD BANG) WHILE WEARING DEVICE IN EAR. USER REMOVED THE DEVICE AND SAW THE HOUSING WAS DISLOCATED AND THE DEVICE FELT VERY WARM. NO PHYSICAL HARM WAS REPORTED, NO INCREASE OF HEARING LOSS OR TINNITUS AS A RESULT OF THIS WAS REPORTED. THE USER HAS NOT SEEN A DOCTOR. HOT FEELING AND SCARRING (NO PHYSICAL HARM) WAS REPORTED. USER WAS WEARING THE HEARING AID DURING TRIAL PERIOD. WAS USING BATTERIES FROM VARTA CALLED POWER ONE EVOLUTION, WHICH WAS PROVIDED BY THE HEARING CARE PROVIDER. FURTHER INVESTIGATION TO BE CONDUCTED.
IT WAS REPORTED THAT A HEARING AID OVERHEATED AND EXPLODED (LOUD BANG) WHILE WEARING DEVICE IN EAR. USER REMOVED THE DEVICE AND SAW THE HOUSING WAS DISLOCATED AND THE DEVICE FELT VERY WARM. NO PHYSICAL HARM WAS REPORTED, NO INCREASE OF HEARING LOSS OR TINNITUS AS A RESULT OF THIS WAS REPORTED. THE USER HAS NOT SEEN A DOCTOR. HOT FEELING AND SCARRING (NO PHYSICAL HARM) WAS REPORTED. USER WAS WEARING THE HEARING AID DURING TRIAL PERIOD. WAS USING BATTERIES FROM VARTA CALLED POWER ONE EVOLUTION, WHICH WAS PROVIDED BY THE HEARING CARE PROVIDER. FURTHER INVESTIGATION TO BE CONDUCTED. 17-OCT-2024: DESPITE ATTEMPTS NO FURTHER FOLLOW UP INFORMATION RECEIVED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 223987 | GN RESOUND | HEARING AID, AIR CONDUCTION WITH WIRELESS TECHNOLOGY | OSM | GN HEARING A/S | 21211609 | 05708296178865 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | NA | Male |